

Yuqing Lou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2020916/publications.pdf>

Version: 2024-02-01

59
papers

1,106
citations

516710

16
h-index

434195

31
g-index

65
all docs

65
docs citations

65
times ranked

2047
citing authors

#	ARTICLE	IF	CITATIONS
1	The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma. <i>Cancer Medicine</i> , 2022, 11, 1299-1309.	2.8	6
2	Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 28-39.	2.2	5
3	Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia Signals. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 840466.	3.7	0
4	The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma. <i>Cancer Letters</i> , 2022, 532, 215599.	7.2	4
5	EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study. <i>Clinical Lung Cancer</i> , 2021, 22, e395-e404.	2.6	4
6	PIGF knockdown attenuates hypoxia-induced stimulation of cell proliferation and glycolysis of lung adenocarcinoma through inhibiting Wnt/ β 2-catenin pathway. <i>Cancer Cell International</i> , 2021, 21, 18.	4.1	3
7	Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis. <i>Cell Death and Disease</i> , 2021, 12, 170.	6.3	13
8	Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery. <i>Lung Cancer</i> , 2021, 154, 124-130.	2.0	2
9	ctDNA-Profilng-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients. <i>Frontiers in Genetics</i> , 2021, 12, 723670.	2.3	9
10	TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 732125.	4.8	10
11	A Novel Risk-Score Model With Eight MiRNA Signatures for Overall Survival of Patients With Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 741112.	2.3	3
12	The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus. <i>Frontiers in Oncology</i> , 2021, 11, 745150.	2.8	2
13	Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies. <i>International Journal of Cancer</i> , 2020, 146, 3124-3133.	5.1	40
14	Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. <i>Journal of International Medical Research</i> , 2020, 48, 030006051988727.	1.0	27
15	Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study. <i>Targeted Oncology</i> , 2020, 15, 175-184.	3.6	13
16	Does surgically resected small-cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?. <i>Thoracic Cancer</i> , 2020, 11, 1239-1244.	1.9	7
17	CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1049.	2.8	13
18	Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIs. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5387-5394.	2.0	1

#	ARTICLE	IF	CITATIONS
19	Serum TNFR1: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 4150-4156.	3.6	1
20	Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 739-747.	1.8	21
21	Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung Cancer. <i>Advanced Science</i> , 2019, 6, 1900721.	11.2	30
22	Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma. <i>Targeted Oncology</i> , 2019, 14, 423-431.	3.6	3
23	Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line. <i>Frontiers in Oncology</i> , 2019, 9, 886.	2.8	20
24	Adjuvant Chemotherapy Improves Survival in Surgically Resected Stage IB Squamous Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1683-1689.	1.3	6
25	Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 2392-2400.	1.5	12
26	Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases. <i>Journal of Cardiothoracic Surgery</i> , 2019, 14, 63.	1.1	3
27	Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. <i>Oncologist</i> , 2019, 24, 157-e64.	3.7	79
28	Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. <i>European Respiratory Journal</i> , 2019, 53, 1801562.	6.7	61
29	Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells. <i>Journal of Cancer</i> , 2018, 9, 367-374.	2.5	11
30	Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial. <i>International Journal of Cancer</i> , 2017, 141, 1249-1256.	5.1	96
31	Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small cell lung cancer patients with EGFR mutations. <i>International Journal of Cancer</i> , 2017, 140, 1645-1652.	5.1	34
32	Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 347-353.	1.1	50
33	MFN2 might be a risk factor for lung adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, e13007-e13007.	1.6	1
34	Isolation and expansion of OCT4/Sox2 specific cytotoxic T lymphocytes in vitro. <i>Journal of Clinical Oncology</i> , 2017, 35, e14578-e14578.	1.6	0
35	β-catenin inhibitors suppress cells proliferation and promote cells apoptosis in PC9 lung cancer stem cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 11968-11978.	0.5	5
36	The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6479-6484.	2.0	3

#	ARTICLE	IF	CITATIONS
37	EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation. <i>Scientific Reports</i> , 2016, 6, 36371.	3.3	6
38	Transcriptional profiling revealed the anti-proliferative effect of MFN2 deficiency and identified risk factors in lung adenocarcinoma. <i>Tumor Biology</i> , 2016, 37, 8643-8655.	1.8	10
39	EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. <i>Lung Cancer</i> , 2016, 96, 87-92.	2.0	81
40	Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1325-1330.	2.5	20
41	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 309-314.	2.6	13
42	Knockdown of HNRNPA1 inhibits lung adenocarcinoma cell proliferation through cell cycle arrest at G0/G1 phase. <i>Gene</i> , 2016, 576, 791-797.	2.2	56
43	Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer. <i>PLoS Genetics</i> , 2016, 12, e1005895.	3.5	144
44	Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 68360-68370.	1.8	20
45	Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations. <i>Oncotarget</i> , 2016, 7, 68442-68448.	1.8	13
46	MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 83051-83059.	1.8	12
47	Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Thoracic Disease</i> , 2016, 8, 68-78.	1.4	6
48	Wnt blockers inhibit the proliferation of lung cancer stem cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2399.	4.3	31
49	Mitofusin-2 over-expresses and leads to dysregulation of cell cycle and cell invasion in lung adenocarcinoma. <i>Medical Oncology</i> , 2015, 32, 132.	2.5	45
50	HSG-MLF1IP axis as potential targets for lung adenocarcinoma treatment.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13591-e13591.	1.6	0
51	XPA gene rs1800975 single nucleotide polymorphism and lung cancer risk: a meta-analysis. <i>Tumor Biology</i> , 2014, 35, 6607-6617.	1.8	13
52	The Connexin37 Gene C1019T Polymorphism and Risk of Coronary Artery Disease: A Meta-analysis. <i>Archives of Medical Research</i> , 2014, 45, 21-30.	3.3	7
53	Heterogeneous Effect of Two Selectin Gene Polymorphisms on Coronary Artery Disease Risk: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e88152.	2.5	11
54	Randomized, placebo-controlled study of vinorelbine plus cisplatin with celecoxib and serum VEGF before treatment as a biomarker for patients with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19066-e19066.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Construction and efficacy identification of the lentiviral vector harboring RNAi based on the hyperplasia suppressor gene (<i>HSG</i>).. <i>Journal of Clinical Oncology</i> , 2014, 32, e22177-e22177.	1.6	0
56	Association of natriuretic peptide polymorphisms with left ventricular dysfunction in southern Han Chinese coronary artery disease patients. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 7148-57.	0.5	2
57	NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis. <i>Tumor Biology</i> , 2013, 34, 3967-3979.	1.8	8
58	Clinical analysis of Gefitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations. <i>Thoracic Cancer</i> , 2013, 4, 433-439.	1.9	1
59	Erlotinib as neoadjuvant treatment in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation (NCT01217619, ESTERN).. <i>Journal of Clinical Oncology</i> , 2012, 30, e17551-e17551.	1.6	1